← Leaderboards
Vikas P Sukhatme
Beth Israel Deaconess Medical Center
$7,880,174
Attributed
$7,880,174
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.7M · FY2005–08$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
Funding mix
By agency
NIH$12,440,093 · 8
By mechanism
M01$4,559,919 · 1
R01$4,323,788 · 4
T32$2,547,666 · 1
R21$1,008,720 · 2
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- David McDermott$9,360,637
- Zhao-Yi Wang$2,879,953
- Raghu Kalluri$29,360,132
- Frank W Sellke$18,106,428
- Dong-Er Zhang$30,254,830
Others in their field
Top investigators on “Angiogenesis Inhibitors”
- Walter John Curran · Thomas Jefferson University$26,641,549
- David Heimbrook · Leidos Biomedical Research, Inc.$24,469,358
- David R Harder · Medical College Of Wisconsin$16,163,720
- Elizabeth Marion Jaffee · Johns Hopkins University$12,679,276
- Garrett M Brodeur · Children'S Hospital Of Philadelphia$12,442,187
- Erwin G Van Meir · University Of Alabama At Birmingham$11,726,130
Research focus
Angiogenesis InhibitorsLaboratory MouseCell ProliferationDrug Screening /EvaluationNeoplasm /Cancer ChemotherapyGene ExpressionAngiogenesisTranscription FactorCell LineHuman SubjectProtein PurificationHuman Therapy EvaluationClinical ResearchBiological Signal TransductionProtein Structure FunctionSite Directed MutagenesisPatient Oriented ResearchCell MigrationMitogen Activated Protein KinasePolymerase Chain ReactionApoptosisCombination ChemotherapyCell CycleProtein Kinase C
Grant awards (29)
General Clinical Research Center$467,785
M01 · FY2008 · RR · contact PI
Research Training in Nephrology$371,921
T32 · FY2008 · DK · contact PI
General Clinical Research Center$4,092,134
M01 · FY2007 · RR · contact PI
Research Training in Nephrology$308,580
T32 · FY2007 · DK · contact PI
Generation of Antiangiogenic Activity for Cancer Treat.$270,081
R01 · FY2007 · CA · contact PI
Generation of Antiangiogenic Activity for Cancer Treat.$272,279
R01 · FY2006 · CA · contact PI
RESEARCH TRAINING IN NEPHROLOGY$254,468
T32 · FY2006 · DK · contact PI
RESEARCH TRAINING IN NEPHROLOGY$339,443
T32 · FY2005 · DK
Generation of Antiangiogenic Activity for Cancer Treat.$326,046
R01 · FY2005 · CA
RESEARCH TRAINING IN NEPHROLOGY$331,293
T32 · FY2004 · DK
Generation of Antiangiogenic Activity for Cancer Treat.$319,302
R01 · FY2004 · CA
COMBINATION ANTIANGIOGENIC THERAPY FOR ADVANCED MELANOMA$314,610
R21 · FY2004 · CA
ENDOSTATIN ACTION--SIGNALING AND MUTANTS$368,897
R01 · FY2003 · CA
COMBINATION ANTIANGIOGENIC THERAPY FOR ADVANCED MELANOMA$346,110
R21 · FY2003 · CA
Generation of Antiangiogenic Activity for Cancer Treat.$310,559
R01 · FY2003 · CA
RESEARCH TRAINING IN NEPHROLOGY$272,830
T32 · FY2003 · DK
ENDOSTATIN ACTION--SIGNALING AND MUTANTS$359,919
R01 · FY2002 · CA
RESEARCH TRAINING IN NEPHROLOGY$312,929
T32 · FY2002 · DK
THREE VHL TUMOR SUPPRESSOR TARGETS IN RENAL CANCER$153,391
R01 · FY2002 · CA
ENDOSTATIN ACTION--SIGNALING AND MUTANTS$351,207
R01 · FY2001 · CA
WILMS TUMOR-1 GENE REGULATION IN KIDNEY DEVELOPMENT$332,457
R01 · FY2001 · DK
THREE VHL TUMOR SUPPRESSOR TARGETS IN RENAL CANCER$299,612
R01 · FY2001 · CA
OVARIAN CANCER ANTI ANGIOGENIC FACTOR$174,000
R21 · FY2001 · CA
RESEARCH TRAINING IN NEPHROLOGY$124,609
T32 · FY2001 · DK
ENDOSTATIN ACTION--SIGNALING AND MUTANTS$342,742
R01 · FY2000 · CA
WILMS TUMOR-1 GENE REGULATION IN KIDNEY DEVELOPMENT$324,645
R01 · FY2000 · DK
THREE VHL TUMOR SUPPRESSOR TARGETS IN RENAL CANCER$292,651
R01 · FY2000 · CA
RESEARCH TRAINING IN NEPHROLOGY$231,593
T32 · FY2000 · DK
OVARIAN CANCER ANTI ANGIOGENIC FACTOR$174,000
R21 · FY2000 · CA